Key statistics
As of last trade, Coherus Oncology Inc (8C5:DUS) traded at 1.33, 122.24% above the 52 week low of 0.5998 set on Jun 26, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.33 |
|---|---|
| High | 1.33 |
| Low | 1.33 |
| Bid | 1.33 |
| Offer | 1.42 |
| Previous close | 1.40 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 120.87m |
| Free float | 95.40m |
| P/E (TTM) | -- |
| Market cap | 194.60m USD |
| EPS (TTM) | -1.62 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 07:10 GMT.
More ▼
- Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
- Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
- Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
- Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
- Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
- Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
- Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
- Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
- Coherus Oncology to Participate in Upcoming Investor Conferences
More ▼
